Changeflow GovPing Healthcare & Life Sciences FDA Completeness Assessment Correspondence
Routine Notice Added Final

FDA Completeness Assessment Correspondence

Favicon for www.regulations.gov Regs.gov: Food and Drug Administration
Published
Detected
Email

Summary

The FDA has posted Completeness Assessment Correspondence related to drug applications. This notice provides information from the Center for Drug Evaluation and Research (CDER) regarding the completeness of submitted applications.

Published by FDA on regulations.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The FDA has made available Completeness Assessment Correspondence authored by CDER, dated March 23, 2026. This document is associated with the FDA-2026-P-2258-0007 docket and indicates a new piece of information has been added regarding the assessment of drug application completeness.

Compliance officers in the pharmaceutical sector should review this correspondence to understand any potential implications for drug application submissions and review processes. While this appears to be an informational notice, it may contain details relevant to the completeness criteria applied by the FDA. No immediate compliance actions are indicated, but awareness of this communication is advised.

Archived snapshot

Mar 24, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Content

There are no documents available to view or download

Attachments 1

Completeness Assessment Correspondence

More Information
- Author(s) CDER
Download

Get daily alerts for Regs.gov: Food and Drug Administration

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from FDA.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
FDA
Published
March 23rd, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
FDA-2026-P-2258-0007
Docket
FDA-2026-P-2258-0007

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Application Submission
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Compliance
Compliance frameworks
FDA 21 CFR Part 11 GxP
Topics
Drug Approval Process

Get alerts for this source

We'll email you when Regs.gov: Food and Drug Administration publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!